Literature DB >> 21220773

Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection.

Nicole L Yonkers1, Scott Sieg, Benigno Rodriguez, Donald D Anthony.   

Abstract

BACKGROUND: Chronic hepatitis C virus (HCV) infection is characterized by reduced numbers of functional HCV-specific T cells. In addition, chronically HCV-infected individuals have reduced response to vaccine. Alterations in naive CD4 T cell phenotype or function may contribute to these immune impairments.
METHODS: Using flow cytometric analysis and enzyme-linked immunospot assay, we examined peripheral naive CD4 T cell phenotype and function in chronically HCV-infected patients and control subjects.
RESULTS: We observed significantly lower absolute cell numbers of naive CD4 T cells in HCV-infected patients, localized to the CD127(+)CD25(low/-) and CD31(+) (RTE) subsets. Moreover, we found greater percentages of naive cells expressing CD25 and KI67 in HCV-infected patients, consistent with immune activation, further supported by higher plasma sCD27 levels. Functional analysis revealed an intact interferon-γ response to allogeneic B cell stimulus. However, after direct TCR stimulation, naive CD4 T cells from HCV-infected patients had altered up-regulation of KI67 and CD25 and less CD27 expression. The latter was associated with elevated baseline activation state. In addition, naive CD4 T cells from HCV-infected patients were more susceptible to cell death.
CONCLUSIONS: These numerical and functional defects may contribute to inadequate formation of virus and neoantigen-specific T cell responses during chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220773      PMCID: PMC3072735          DOI: 10.1093/infdis/jiq101

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  CD27 is required for generation and long-term maintenance of T cell immunity.

Authors:  J Hendriks; L A Gravestein; K Tesselaar; R A van Lier; T N Schumacher; J Borst
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

3.  A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex.

Authors:  R Q Hintzen; R de Jong; C E Hack; M Chamuleau; E F de Vries; I J ten Berge; J Borst; R A van Lier
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

4.  Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.

Authors:  R A van Lier; J Borst; T M Vroom; H Klein; P Van Mourik; W P Zeijlemaker; C J Melief
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

5.  Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.

Authors:  M Wiedmann; U G Liebert; U Oesen; H Porst; M Wiese; S Schroeder; U Halm; J Mössner; F Berr
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

6.  Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion.

Authors:  R Arens; K Tesselaar; P A Baars; G M van Schijndel; J Hendriks; S T Pals; P Krimpenfort; J Borst; M H van Oers; R A van Lier
Journal:  Immunity       Date:  2001-11       Impact factor: 31.745

7.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 8.  Adaptive immune responses in acute and chronic hepatitis C virus infection.

Authors:  David G Bowen; Christopher M Walker
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool.

Authors:  Jenny Hendriks; Yanling Xiao; Jannie Borst
Journal:  J Exp Med       Date:  2003-10-27       Impact factor: 14.307

View more
  28 in total

1.  In utero activation of fetal memory T cells alters host regulatory gene expression and affects HIV susceptibility.

Authors:  Kevin L Steiner; Indu Malhotra; Peter L Mungai; Eric M Muchiri; Arlene E Dent; Christopher L King
Journal:  Virology       Date:  2012-01-26       Impact factor: 3.616

2.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

3.  Memory regulatory T cells reside in human skin.

Authors:  Robert Sanchez Rodriguez; Mariela L Pauli; Isaac M Neuhaus; Siegrid S Yu; Sarah T Arron; Hobart W Harris; Sara Hsin-Yi Yang; Bryan A Anthony; Francis M Sverdrup; Elisabeth Krow-Lucal; Tippi C MacKenzie; David S Johnson; Everett H Meyer; Andrea Löhr; Andro Hsu; John Koo; Wilson Liao; Rishu Gupta; Maya G Debbaneh; Daniel Butler; Monica Huynh; Ethan C Levin; Argentina Leon; William Y Hoffman; Mary H McGrath; Michael D Alvarado; Connor H Ludwig; Hong-An Truong; Megan M Maurano; Iris K Gratz; Abul K Abbas; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

4.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

5.  Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis.

Authors:  Angela L Rasmussen; I-Ming Wang; Margaret C Shuhart; Sean C Proll; Yudong He; Razvan Cristescu; Chris Roberts; Victoria S Carter; Christopher M Williams; Deborah L Diamond; Janine T Bryan; Roger Ulrich; Marcus J Korth; Lisa V Thomassen; Michael G Katze
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

6.  Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  J Neuroimmunol       Date:  2014-12-10       Impact factor: 3.478

7.  Periorbital necrotising fasciitis with underlying undiagnosed hepatitis C infection.

Authors:  Nicholas Cereceda-Monteoliva; Hannah Lewis; Sarah Al-Himdani; Christopher Stone
Journal:  BMJ Case Rep       Date:  2019-04-23

8.  Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Authors:  Chelsey J Judge; Johan K Sandberg; Nicholas T Funderburg; Kenneth E Sherman; Adeel A Butt; Minhee Kang; Alan L Landay; Michael M Lederman; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

9.  Altered T-cell subsets in HIV-1 natural viral suppressors (elite controllers) with hepatitis C infection.

Authors:  Mohammad M Sajadi; Robert R Redfield; Rohit Talwani
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

10.  CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.

Authors:  Jessica A Hutter Saunders; Katherine A Estes; Lisa M Kosloski; Heather E Allen; Kathryn M Dempsey; Diego R Torres-Russotto; Jane L Meza; Pamela M Santamaria; John M Bertoni; Daniel L Murman; Hesham H Ali; David G Standaert; R Lee Mosley; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.